ERBB2 and breast cancer: HER2+ breast cancer patients treated with neoadjuvant trastuzumab (targets HER2) achieved a pathological complete response (pCR), and were characterized by a higher abundance of Clostridiales bacteria and a lower abundance of Bacteroidales.